876 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Corient IA LLC

Key Points

• Corient IA LLC purchased 876 shares of IDEXX Laboratories, valued at approximately $368,000, reflecting growing interest from institutional investors, who own 87.84% of the company's stock.
• IDEXX Laboratories reported quarterly earnings of $3.63 per share, surpassing expectations, with a revenue of $1.11 billion, marking a 10.6% increase from the previous year.
• Insider transactions indicated significant sales, with two executives selling a combined total of 15,554 shares valued at over $9.7 million amid stock performance that has seen highs of $688.12 in the past year.

Corient IA LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 876 shares of the company's stock, valued at approximately $368,000.

A number of other institutional investors have also made changes to their positions in IDXX. Gabelli Funds LLC increased its stake in shares of IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares during the period. United Capital Financial Advisors LLC increased its stake in shares of IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares during the period. NewEdge Advisors LLC increased its stake in shares of IDEXX Laboratories by 4.8% in the fourth quarter. NewEdge Advisors LLC now owns 11,478 shares of the company's stock worth $4,745,000 after purchasing an additional 530 shares during the period. CANADA LIFE ASSURANCE Co increased its stake in shares of IDEXX Laboratories by 3.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 73,395 shares of the company's stock worth $30,330,000 after purchasing an additional 2,408 shares during the period. Finally, Commerce Bank increased its stake in shares of IDEXX Laboratories by 7.0% in the fourth quarter. Commerce Bank now owns 12,388 shares of the company's stock worth $5,122,000 after purchasing an additional 808 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the topic of several research reports. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target on the stock. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research note on Monday, August 4th. Leerink Partners boosted their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, Morgan Stanley boosted their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $12.50 during trading on Friday, reaching $645.55. 352,260 shares of the company traded hands, compared to its average volume of 829,808. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock's 50 day moving average price is $569.94 and its two-hundred day moving average price is $493.97. The company has a market cap of $51.64 billion, a price-to-earnings ratio of 53.75, a P/E/G ratio of 4.10 and a beta of 1.49. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company's stock, valued at $52,650,885.78. The trade was a 25.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Lane sold 8,411 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,870 shares of company stock worth $32,877,757 over the last ninety days. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.